EAM
AKBA icon

Exome Asset Management’s Akebia Therapeutics AKBA Stock Holding History

Exome Asset Management’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-189,087
Closed -$363K – 64
2025
Q1 		$363K Sell
189,087
-16,869
-8% -$34.4K 0.32% 47
2024
Q4 		$391K Buy
+205,956
New +$358K 0.29% 54

Other funds holding AKBA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Exome Asset Management's AKBA Position: Q2 2025 in Review

Exome Asset Management sold out of Akebia Therapeutics (AKBA) in Q2 2025, closing a stake of 189,087 shares — an estimated $363K sold.

Exome Asset Management first reported a position in AKBA in Q4 2024 and held it in 2 quarters. The position peaked at $391K in Q4 2024. 157 funds tracked by Wall St. Rank hold AKBA as of Q2 2025.

  • Exome Asset Management reported no remaining Akebia Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Exome Asset Management sold 189,087 Akebia Therapeutics shares in Q2 2025, an estimated $363K.
  • Exome Asset Management first reported a position in Akebia Therapeutics in Q4 2024 and held it in 2 quarters.
  • Exome Asset Management's Akebia Therapeutics position peaked at $391K in Q4 2024.
  • 157 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2025.

Based on Exome Asset Management's 13F filing for Q2 2025, filed 14 Aug 2025.